		JAN 10	2000 44				Sheet 1 of 3			
FORM PTO	1449	2			File No. 98	File No. 98-10D1 Se				
(REV 2-32) TRADEMINE										
,		FORMATION			Applicant(s)):				
STATEMENT BY APPLICANT RECEIVED Wen-feng Xu et al.										
				JAN	1 3 2050 ing Date:		Group: 1646			
August 10, 1999										
			U	.S. PATENT DOCU	MENTS					
EXAMINER				SUBCLASS	FILING DATE					
INITIAL	A1	NUMBER -09/032,397	N/A	Coughlin and Kahn			IF APPROPRIATE			
						 				
n										
			İ							
			FOR	EIGN PATENT DO	CUMENTS					
EXAMINER		DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	FILING DATE			
INITIAL		NUMBER					IF APPROPRIATE			
			-							
-			<u> </u>	<u></u>		<u> </u>				
(DTHE A2			luding Author, Tit						
2	_^~			ular cloning of a functiona ceptor activation," <u>Cell</u> 64	<u>-</u>		el proteolytic			
	A2 -						- 21			
n	A3		Rasmussen et al., "cDNA cloning and expression of a hamster α-thrombin receptor coupled to Ca ²⁺ mobilization," <u>FEBS Lett.</u> 288:123-128, August, 1991.							
	_A4	Nystedt et al., "Molecular cloning of a potential proteinase activated receptor," Proc. Nat'l Acad.								
			Sci. USA 91:9208-9212, September 1994.							
	٨٤	37								
	A5_		Vu et al., "Domains specifying thrombin-receptor interaction," <u>Nature</u> 353:674-677, October 17, 1997.							
	A6	Cor	nolly et al "	Role of the thrombin recei	ptor in development	and evidence	for a second recentor."			
			Connolly et al., "Role of the thrombin receptor in development and evidence for a second receptor," Nature 381:516-519, June 6, 1996.							
9	Coughlin, "Protease activated receptors start a family," Proc. Nat'l Acad. Sci. USA 91:9200-9202,									
		Sep	September, 1994.							
1	Molino et al., "Endothelial cell thrombin receptors and PAR-2," J. Biol. Chem. 272:11133-11141, April 25, 1997.									
Examiner				Date c	onsidered					

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 2 of 3

FORM PTO 1449
(REV 2-32)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

File	No.	98-10D1

Serial No. 09/371,333

Αp	plican	t(s):

Wen-feng Xu et al.

Filing Date: August 10, 1999 Group: 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
						02/27/98
					<u> </u>	<u> </u>
		ļ				
		ļ				
		ļ				
1						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, Etc.)

		·
2	_B1	Gerszten et al., "Specificity of the thrombin receptor for agonist peptide is defined by its extracellular surface," Nature 368:648-651, April 14, 1994.
9	B2	Ishii et al., "Inhibition of thrombin receptor signaling by a G-protein coupled receptor kinase," <u>J. Biol. Chem.</u> 269:1125-1130, January 14, 1994.
9/	ВЗ	Probst et al., "Sequence alignment of the G-protein coupled receptor superfamily," <u>DNA Cell Biol.</u> 11:1-20, 1997.
<i>i</i> /		
V	B4	Ishihara et al., "Protease-activated receptor 3 is a second thrombin receptor in humans," Nature 386:502-506, April 3, 1997.
	5-	
9/	B5	EST from Incyte Pharmaceuticals, Inc., 373881.
V	B6	EST from Incyte Pharmaceuticals, Inc., 2189250.
7/	В7	EST from Incyte Pharmaceuticals, Inc., 2899749.

Examiner

Date considered

Joh un

11-3-2000

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

٠		E J	Car			(Sheet 3 of 3	
9		JAN 1 0 P	A RECEIVED	File No. 98-10D1			Serial No. 09/371,333	
IN S	FORMATION	DISCL OSOF APPLICAN	€ IT	Applicant(s) Wen-feng X				
				Filing Date: August 10, 1		Gr	oup: 1646	
		U.	S. PATENT DOCUMEN	NTS		,		
	DOCUMENT NUMBER	DATE	NAME	CLASS SUBCLASS			FILING DATE IF APPROPRIATE	
				 -				
_								
					 		· - · · -	
_								
					<u> </u>			
		FOR	EIGN PATENT DOCUM	MENTS				
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	3	FILING DATE IF APPROPRIATE	
	, ,				 			
		-	-	- 			 	
	<u> </u>							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, Etc.) EST from Incyte Pharmaceuticals, Inc., 3218437.

Examiner

FORM PTO 1449 (REV 2-32)

EXAMINER

EXAMINER INITIAL

INITIAL

Date considered

11-1-2000

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.